Ingrid Choong
Plus aucun poste en cours
Fortune : 5 591 $ au 31/03/2024
Profil
Ingrid C.
Choong worked as a Senior Scientist at Sunesis Pharmaceuticals, Inc. from 1999 to 2008.
She then served as an Investor Relations Officer at Eiger BioPharmaceuticals, Inc. In 2008, she returned to Eiger BioPharmaceuticals, Inc. as the SVP-Clinical Development & Head-Investor Relations.
In terms of education, Dr. Choong obtained an undergraduate degree from the California Institute of Technology and a doctorate from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/08/2023 | 1 117 ( 0,08% ) | 5 591 $ | 31/03/2024 |
Anciens postes connus de Ingrid Choong
| Sociétés | Poste | Fin |
|---|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2023 |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Investor Relations Contact | 29/03/2016 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2008 |
Formation de Ingrid Choong
| California Institute of Technology | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
